Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Meeting Abstract
| Authors: | Dumbrava, E. I.; Sharma, M. R.; Carvajal, R. D.; Catenacci, D.; Emens, L. A.; Gadgeel, S. M.; Hanna, G. J.; Juric, D.; Kang, Y. K.; Lee, J.; Lee, K. W.; Li, B. T.; Moore, K.; Pegram, M. D.; Pohlmann, P. R.; Rasco, D.; Spira, A.; Tan, A. R.; Ackerman, S. E.; LeBlanc, H.; Dornan, D.; Kowanetz, M.; Alonso, M. N.; Perez, E. A. |
| Abstract Title: | Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700036 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-OT-03-02 |
| Notes: | Meeting Abstract: OT-03-02 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
